20.89
-0.6(-2.79%)
Currency In USD
| Previous Close | 21.49 |
| Open | 21.05 |
| Day High | 21.53 |
| Day Low | 20.59 |
| 52-Week High | 29.56 |
| 52-Week Low | 7.18 |
| Volume | 642,979 |
| Average Volume | 839,117 |
| Market Cap | 1.48B |
| PE | -7.2 |
| EPS | -2.9 |
| Moving Average 50 Days | 24.03 |
| Moving Average 200 Days | 19.33 |
| Change | -0.6 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $1,098.9 as of December 04, 2024 at a share price of $20.89. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $752.52 as of December 04, 2024 at a share price of $20.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Dec 02, 2024 12:00 PM GMT
SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, toda
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2024 12:00 PM GMT
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, toda
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
GlobeNewswire Inc.
Nov 20, 2024 9:00 PM GMT
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- N